{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:34:30Z","timestamp":1778952870595,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trial eligibility criteria are necessary for safety and target population homogeneity; however, increasingly restrictive organ function eligibility rarely precludes standard therapies and impedes clinical application of trial results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, retrospective study applied safety-related eligibility criteria from 4 landmark phase 3 trials (GALLIUM, RELEVANCE, StiL NHL1, BRIGHT) to 528 treatment-naive patients with follicular lymphoma receiving standard immunochemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 55% of included patients were ineligible for at least 1 study, and 12% were ineligible for all 4 studies. Ineligible patients were more likely to be older than 60\u2009years of age and have poorer performance status than eligible patients (P\u2009&amp;lt;\u2009.05). There was no difference between response rate or progression-free survival among eligible vs ineligible patients. Patients ineligible for all trials had inferior 5-year overall survival than patients eligible for at least 1 study (69% vs 92%; P\u2009&amp;lt;\u2009.001). More than half of deaths were due to causes other than lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current trials select populations with favorable overall survival despite similar disease-based outcomes. Patients suitable for standard chemoimmunotherapy should not be routinely excluded based on age, performance status, or organ function from frontline randomized trials with progression-free survival primary endpoints. There is a substantial need to broaden trial eligibility to include all patients fit for standard treatment to correctly benchmark new therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf174","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:04:04Z","timestamp":1751443444000},"page":"2240-2248","source":"Crossref","is-referenced-by-count":2,"title":["Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-321X","authenticated-orcid":false,"given":"Kimberly S Q","family":"Wong","sequence":"first","affiliation":[{"name":"Olivia Newton John Cancer Research Institute at Austin Health , Heidelberg, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3094-8867","authenticated-orcid":false,"given":"Arina","family":"Martynchyk","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer Research Institute at Austin Health , Heidelberg, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Krisnadi","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdner Hospital , Nedlands, WA,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-3271","authenticated-orcid":false,"given":"Fiona","family":"Swain","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital , Woollongabba, QLD,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-3113","authenticated-orcid":false,"given":"Ahmad","family":"Zargari","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-0642","authenticated-orcid":false,"given":"Luke","family":"Cassidy","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Sydney , Darlinghurst, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-2650","authenticated-orcid":false,"given":"Georgia","family":"Mills","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Sydney , Darlinghurst, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-116X","authenticated-orcid":false,"given":"Kenneth","family":"Lim","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne , Fitzroy, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2590-4651","authenticated-orcid":false,"given":"Jeremy","family":"Gervasi","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer Research Institute at Austin Health , Heidelberg, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5524-5077","authenticated-orcid":false,"given":"Portia","family":"Smallbone","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital , Murdoch, WA,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2972-186X","authenticated-orcid":false,"given":"Jenny","family":"Wang","sequence":"additional","affiliation":[{"name":"Gold Coast University Hospital , Southport, QLD,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5040-1142","authenticated-orcid":false,"given":"Olivia","family":"Slifirski","sequence":"additional","affiliation":[{"name":"Eastern Health , Box Hill, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9215-1441","authenticated-orcid":false,"given":"Zoe","family":"Loh","sequence":"additional","affiliation":[{"name":"Northern Health , Epping, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan","family":"Cheah","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdner Hospital , Nedlands, WA,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9934","authenticated-orcid":false,"given":"Colm","family":"Keane","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital , Woollongabba, QLD,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-0682","authenticated-orcid":false,"given":"Gareth","family":"Gregory","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-4003","authenticated-orcid":false,"given":"Masa","family":"Lasica","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne , Fitzroy, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-2380","authenticated-orcid":false,"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer Research Institute at Austin Health , Heidelberg, VIC,","place":["Australia"]},{"name":"Northern Health , Epping, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0540","authenticated-orcid":false,"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital , Murdoch, WA,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-1399","authenticated-orcid":false,"given":"Tara","family":"Cochrane","sequence":"additional","affiliation":[{"name":"Gold Coast University Hospital , Southport, QLD,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0096-7764","authenticated-orcid":false,"given":"Denise","family":"Lee","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer Research Institute at Austin Health , Heidelberg, VIC,","place":["Australia"]},{"name":"Eastern Health , Box Hill, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Hawkes","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer Research Institute at Austin Health , Heidelberg, VIC,","place":["Australia"]},{"name":"School of Public Health and Preventive Medicine, Monash University , St Kilda, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025110923131788000_djaf174-B1","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/j.clbc.2020.04.002","article-title":"Elucidating determinants of survival disparities among a real-world cohort of metastatic breast cancer patients: a national cancer database analysis","volume":"20","author":"Statler","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"2025110923131788000_djaf174-B2","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1200\/jco.20.01935","article-title":"Impact of organ function-based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind?","volume":"39","author":"Khurana","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025110923131788000_djaf174-B3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjh.17436","article-title":"Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years","volume":"193","author":"Loh","year":"2021","journal-title":"Br J Haematol"},{"key":"2025110923131788000_djaf174-B4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025110923131788000_djaf174-B5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025110923131788000_djaf174-B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/edbk_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025110923131788000_djaf174-B7","doi-asserted-by":"publisher","first-page":"dju002","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials","volume":"106","author":"Unger","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025110923131788000_djaf174-B8","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: Real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"key":"2025110923131788000_djaf174-B9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-a population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"key":"2025110923131788000_djaf174-B10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/jha2.870","article-title":"Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed\/refractory diffuse large B-cell lymphoma in routine care: an Australian Lymphoma and Related Diseases Registry project","volume":"5","author":"Shaw","year":"2024","journal-title":"EJHaem"},{"key":"2025110923131788000_djaf174-B11","doi-asserted-by":"publisher","first-page":"CD006560","DOI":"10.1002\/14651858.CD006560.pub4","article-title":"Interventions for improving outcomes in patients with multimorbidity in primary care and community settings","volume":"1","author":"Smith","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025110923131788000_djaf174-B12","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1182\/blood-2022-156376","article-title":"Impact of trial eligibility criteria on outcomes of 1,245 patients with follicular lymphoma treated in the real-world setting: a Danish population-based study","volume":"140","author":"Bennedsen","year":"2022","journal-title":"Blood"},{"key":"2025110923131788000_djaf174-B13","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2025110923131788000_djaf174-B14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/jco.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"2025110923131788000_djaf174-B15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"2025110923131788000_djaf174-B16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"2025110923131788000_djaf174-B17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2025110923131788000_djaf174-B18","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"2025110923131788000_djaf174-B19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2025110923131788000_djaf174-B20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/jco.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025110923131788000_djaf174-B21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025110923131788000_djaf174-B22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025110923131788000_djaf174-B23","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1182\/bloodadvances.2022007687","article-title":"Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER\/LEO cohort analysis","volume":"6","author":"Luan","year":"2022","journal-title":"Blood Adv"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf174\/63723717\/djaf174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2240\/63723717\/djaf174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2240\/63723717\/djaf174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T04:13:21Z","timestamp":1762748001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/11\/2240\/8196167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,10]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf174","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,10]]}}}